17:57 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Melior begins Phase IIb trial for Type II diabetes candidate MLR-1023

Melior Discovery Inc. (Exton, Pa.) spinout Melior Pharmaceuticals I Inc. began a Phase IIb trial of MLR-1023 to treat adults with Type II diabetes uncontrolled on metformin. The 12-week, double-blind trial will enroll 400 patients...
20:12 , Jul 7, 2017 |  BC Week In Review  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
22:11 , Jul 3, 2017 |  BC Extra  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
19:51 , Mar 15, 2017 |  BC Week In Review  |  Clinical News

Apatinib: Ph III ANGEL started

LSK began the double-blind, placebo-controlled, international Phase III ANGEL trial to compare oral apatinib daily plus best supportive care (BSC) vs. BSC alone in about 459 patients who have failed ≥2 prior lines of standard...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

MLR-1023: Phase IIa data

A double-blind, U.S. and South Korean Phase IIa trial in 130 Type II diabetics showed that oral MLR-1023 for 4 weeks met the primary endpoint of reducing post-prandial plasma glucose between days 1 and 29...
07:00 , May 16, 2016 |  BC Week In Review  |  Financial News

Acer Therapeutics completes venture financing

Acer Therapeutics Inc. , Cambridge, Mass.   Business: Endocrine/Metabolic   Date completed: 2016-05-09   Type: Venture financing   Raised: $8.2 million   Investors: TVM Life Science Ventures; Bukwang Pharmaceutical Co. Ltd.  ...
07:00 , Mar 21, 2016 |  BioCentury  |  Finance

Multiples in Korea

While Novartis Venture Fund is looking at significant paper gains after a recent IPO by portfolio company Qurient Co. Ltd. (KOSDAQ:115180), the VC's experience is more likely the exception than the rule. The reason is...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

MLR-1023: Phase IIa started

Melior began a double-blind, placebo-controlled, U.S. and South Korea Phase IIa trial to evaluate 100 and 200 mg oral MLR-1023 once or twice daily for 4 weeks in about 120 patients. Bukwang Pharmaceutical Co. Ltd....
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Melior, Bukwang deal

Melior received the first milestone payment under a 2013 deal granting Bukwang exclusive rights to commercialize MLR-1023 in 36 countries in the Asia-Pacific region. The payment was triggered after FDA accepted Melior’s protocol for a...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Financial News

TVM Capital financial update

The seventh fund had targeted $200 million. Last year, TVM said it would cease investing in IT companies, a year after the fund's initial close at $150 million. The firm has $1.3 billion under management....